复方斑蝥含药血清抑制人肝癌Bel-7402细胞增殖的机制研究  

Inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell line Bel-7402 and its molecular mechanism

作　　者：姜新根[1] 肖兰凤[2] 黄树林[1] 刘顺会[1] 

机构地区：[1]广东药学院生命科学与生物制药学院,广东广州510006 [2]广东药学院临床医学院,广东广州510006

出　　处：《广东药学院学报》2011年第2期170-173,共4页Academic Journal of Guangdong College of Pharmacy

基　　金：国家自然科学基金(30572124)

摘　　要：目的探讨复方斑蝥抑制人肝癌Bel-7402细胞增殖的作用机制。方法血清药理学方法制备复方斑蝥血清并处理人肝癌Bel-7402细胞,MTT方法观察其对人肝癌Bel-7402细胞增殖的抑制作用,RT-PCR技术检测其对c-Myc、p53基因表达的影响。结果复方斑蝥含药血清能够显著抑制Bel-7402细胞的增殖,并下调c-Myc和上调p53基因的表达。结论复方斑蝥可能通过影响细胞增殖相关基因的表达抑制Bel-7402细胞的增殖,可作为一种抗肝癌中药复方的研究原型。Objective To investigate the molecular mechanism underlying the inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell line Bel-7402. Methods The compound mylabris serum was prepared based on serum pharmacology and was used to treat human hepatocarcinoma cell line Bel-7402. MTF assay was used to evaluate the inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell; RT-polymerase chain reaction （RT-PCR） was used to evaluate c-Myc and p53 mRNA expressions in human Hepatocarcinoma cell Bel-7402. Results Compound mylabris serum can remarkably inhibit the proliferation of human hepatocarcinoma cell line Bel-7402 in which gene c-Myc was down-regulated, while p53 was up-regulated. Conclusion Compound mylabris possibly affects the expressions of genes related to the proliferation of human hepatocarcinoma cell line Bel- 7402. It is indicated that compound myabris can be used as a prototype for compound traditional Chinese medicine against liver cancer.

关 键 词：复方斑蝥 人肝癌细胞BEL-7402 P53 c-朋弦 细胞增殖 

分 类 号：R285.6[医药卫生—中药学]